Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...
BioSpace2d
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Everyday Health2d
Ulcerative Colitis Diet: What to Eat and Avoid, 7-Day Meal Plan, More
Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...
Daily2d
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
Pharmabiz2d
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
The American Journal of Managed Care2d
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
Equillium reports positive Phase 2 ulcerative colitis study data
Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
EurekAlert!3d
Crohn's & Colitis Congress® spotlights key IBD research findings
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...
gut.bmj5d
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications
Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
Session: Poster and Exhibition Hall Reception Poster Title:PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS ...